Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MoTriColor phase II vinorelbine study in advanced BRAF-like colon cancer
2016-002364-13Phase 2Terminated
- Sponsor
- Netherlands Cancer Institute
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vinorelbine in colon cancer and colorectal cancer (CRC), sponsored by Netherlands Cancer Institute. Primary endpoints: Safety and anti-tumor activity of vinorelbine and Progression-free survival improvement at 6 weeks. Started Oct 2017; status: terminated.
02
Drugs
vinorelbine
03
Conditions
colon cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on 2016-002364-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002364-13.